Base de dados : MEDLINE
Pesquisa : C10.886.659.633.700 [Categoria DeCS]
Referências encontradas : 917 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 92 ir para página                         

  1 / 917 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386443
[Au] Autor:Nakano N; Kinoshita F; Takada H; Nakayama M
[Ad] Endereço:Good Sleep Center Nagoya City University Hospital.
[Ti] Título:[Electromyography Analysis of Rapid Eye Movement Sleep Behavior Disorder].
[So] Source:Nihon Eiseigaku Zasshi;73(1):27-33, 2018.
[Is] ISSN:1882-6482
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Polysomnography (PSG), which records physiological phenomena including brain waves, breathing status, and muscle tonus, is useful for the diagnosis of sleep disorders as a gold standard. However, measurement and analysis are complex for several specific sleep disorders, such as rapid eye movement (REM) sleep behavior disorder (RBD). Usually, brain waves during REM sleep indicate an awakening pattern under relaxed conditions of skeletal and antigravity muscles. However, these muscles are activated during REM sleep when patients suffer from RBD. These activated muscle movements during REM, so-called REM without atonia (RWA) recorded by PSG, may be related to a neurodegenerative disease such as Parkinson's disease. Thus, careful analysis of RWA is significant not only physically, but also clinically. Commonly, manual viewing measurement analysis of RWA is time-consuming. Therefore, quantitative studies on RWA are rarely reported. A software program, developed from Microsoft Office Excel , was used to semiautomatically analyze the RWA ratio extracted from PSG to compare with manual viewing measurement analysis. In addition, a quantitative muscle tonus study was carried out to evaluate the effect of medication on RBD patients. Using this new software program, we were able to analyze RWA on the same cases in approximately 15 min as compared with 60 min in the manual viewing measurement analysis. This software program can not only quantify RWA easily but also identify RWA waves for either phasic or tonic bursts. We consider that this software program will support physicians and scientists in their future research on RBD. We are planning to offer this software program for free to physicians and scientists.
[Mh] Termos MeSH primário: Eletromiografia/métodos
Músculo Esquelético/fisiopatologia
Transtorno do Comportamento do Sono REM/diagnóstico
Transtorno do Comportamento do Sono REM/fisiopatologia
Sono REM/fisiologia
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Masculino
Tono Muscular
Polissonografia
Software
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1265/jjh.73.27


  2 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449901
[Au] Autor:McCarter SJ; St Louis EK; Sandness DJ; Duwell EJ; Timm PC; Boeve BF; Silber MH
[Ad] Endereço:Mayo Center for Sleep Medicine, Mayo Clinic and Foundation, Rochester, MN, USA.
[Ti] Título:Diagnostic REM sleep muscle activity thresholds in patients with idiopathic REM sleep behavior disorder with and without obstructive sleep apnea.
[So] Source:Sleep Med;33:23-29, 2017 May.
[Is] ISSN:1878-5506
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: We aimed to determine whether visual and automated rapid eye movement (REM) sleep without atonia (RSWA) methods could accurately diagnose patients with idiopathic REM sleep behavior disorder (iRBD) and comorbid obstructive sleep apnea (OSA). METHODS: In iRBD patients (n = 15) and matched controls (n = 30) with and without OSA, we visually analyzed RSWA phasic burst durations, phasic, tonic, and "any" muscle activity by 3-s mini-epochs, phasic activity by 30-s (AASM rules) epochs, and automated REM atonia index (RAI). Group RSWA metrics were analyzed with regression models. Receiver operating characteristic (ROC) curves were used to determine the best diagnostic cutoff thresholds for REM sleep behavior disorder (RBD). Both split-night and full-night polysomnographic studies were analyzed. RESULTS: All mean RSWA phasic burst durations and muscle activities were higher in iRBD patients than in controls (p <0.01). Muscle activity (phasic, "any") cutoffs for 3-s mini-epoch scorings were as follows: submentalis (SM) (15.8%, 19.5%), anterior tibialis (AT) (29.7%, 29.7%), and combined SM/AT (39.5%, 39.5%). The tonic muscle activity cutoff was 0.70% and RAI (SM) cutoff 0.86. The phasic muscle burst duration cutoffs were 0.66 s for SM and 0.71 s for AT. Combining phasic burst durations with RSWA muscle activity improved the sensitivity and specificity of iRBD diagnosis. CONCLUSIONS: This study provides evidence for quantitative RSWA diagnostic thresholds applicable in iRBD patients with OSA. Our findings in this study were very similar to those seen in patients with Parkinson's disease-REM sleep behavior disorder (PD-RBD), consistent with a common mechanism and presumed underlying etiology of synucleinopathy in both groups.
[Mh] Termos MeSH primário: Tono Muscular/fisiologia
Músculo Esquelético/fisiopatologia
Transtorno do Comportamento do Sono REM/diagnóstico
Apneia Obstrutiva do Sono/fisiopatologia
Sono REM/fisiologia
[Mh] Termos MeSH secundário: Idoso
Comorbidade
Eletromiografia/métodos
Feminino
Seres Humanos
Masculino
Meia-Idade
Hipotonia Muscular/fisiopatologia
Polissonografia/métodos
Transtorno do Comportamento do Sono REM/complicações
Transtorno do Comportamento do Sono REM/fisiopatologia
Apneia Obstrutiva do Sono/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  3 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28899330
[Au] Autor:Matar E; Lewis SJ
[Ad] Endereço:Brain and Mind Centre, University of Sydney, Sydney, NSW simon.lewis@sydney.edu.au.
[Ti] Título:REM sleep behaviour disorder: not just a bad dream.
[So] Source:Med J Aust;207(6):262-268, 2017 Sep 18.
[Is] ISSN:1326-5377
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia characterised by the loss of the normal atonia during the REM stage of sleep, resulting in overt motor behaviours that usually represent the enactment of dreams. Patients will seek medical attention due to sleep-related injuries or unpleasant dream content. Idiopathic RBD which occurs independently of any other disease occurs in up to 2% of the older population. Meanwhile, secondary RBD is very common in association with certain neurodegenerative conditions. RBD can also occur in the context of antidepressant use, obstructive sleep apnoea and narcolepsy. RBD can be diagnosed with a simple screening question followed by confirmation with polysomnography to exclude potential mimics. Treatment for RBD is effective and involves treatment of underlying causes, modification of the sleep environment, and pharmacotherapy with either clonazepam or melatonin. An important finding in the past decade is the recognition that almost all patients with idiopathic RBD will ultimately go on to develop Parkinson disease or dementia with Lewy bodies. This suggests that idiopathic RBD represents a prodromal phase of these conditions. Physicians should be aware of the risk of phenoconversion. They should educate idiopathic RBD patients to recognise the symptoms of these conditions and refer as appropriate for further testing and enrolment into research trials focused on neuroprotective measures.
[Mh] Termos MeSH primário: Transtorno do Comportamento do Sono REM/diagnóstico
[Mh] Termos MeSH secundário: Clonazepam/uso terapêutico
Seres Humanos
Hipnóticos e Sedativos/uso terapêutico
Melatonina/uso terapêutico
Polissonografia
Transtorno do Comportamento do Sono REM/tratamento farmacológico
Transtorno do Comportamento do Sono REM/etiologia
Transtorno do Comportamento do Sono REM/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 5PE9FDE8GB (Clonazepam); JL5DK93RCL (Melatonin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170914
[St] Status:MEDLINE


  4 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28887374
[Au] Autor:Leclair-Visonneau L; Clairembault T; Coron E; Le Dily S; Vavasseur F; Dalichampt M; Péréon Y; Neunlist M; Derkinderen P
[Ad] Endereço:From Inserm (L.L.-V., T.C., E.C., M.N., P.D.), U1235, Nantes; University Nantes (L.L.-V., T.C., E.C., Y.P., M.N., P.D.); Inserm (L.L.-V., E.C., S.L.D., F.V., P.D.), CIC-04; CHU Nantes (L.L.-V., Y.P.), Department of Clinical Neurophysiology; CHU Nantes (T.C., E.C., F.V., M.N.), Institut des Maladies
[Ti] Título:REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease.
[So] Source:Neurology;89(15):1612-1618, 2017 Oct 10.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine whether REM sleep behavior disorder (RBD) in Parkinson disease (PD) is associated with lesions and dysfunctions of the autonomic nervous system by evaluating enteric phosphorylated α-synuclein histopathology (PASH) and permeability. METHODS: A total of 45 patients with PD were included in this cross-sectional study. RBD was diagnosed on the basis of a standardized clinical interview and confirmed by polysomnography. For each patient, 5 biopsies were taken at the junction between the sigmoid and descending colon during the course of a rectosigmoidoscopy. For the detection of enteric PASH, 2 colonic biopsies were analyzed by immunohistochemistry with antibodies against phosphorylated α-synuclein and PGP9.5 in 43 patients (2 patients were excluded because only 1 biopsy was available). The paracellular permeability and transcellular permeability were evaluated by measuring sulfonic acid and horseradish peroxidase flux, respectively, in the 3 remaining biopsies mounted in Ussing chambers. RESULTS: Enteric PASH was more frequent in the subgroup of patients with PD with RBD compared to patients without RBD (18 of 28, 64.3%, vs 2 of 15, 13.3%, respectively, < 0.01). No differences were observed in intestinal permeability between patients with PD with and without RBD. CONCLUSIONS: Patients with PD and RBD have a greater frequency of synuclein pathology in the enteric nervous system, suggesting that RBD is associated with widespread synuclein neuropathology.
[Mh] Termos MeSH primário: Sistema Nervoso Entérico/patologia
Doença de Parkinson/complicações
Transtorno do Comportamento do Sono REM/etiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Permeabilidade da Membrana Celular/fisiologia
Colonoscopia
Estudos Transversais
Sistema Nervoso Entérico/metabolismo
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Índice de Gravidade de Doença
alfa-Sinucleína/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (alpha-Synuclein)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170910
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000004496


  5 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28847794
[Au] Autor:Suzuki K; Okuma Y; Uchiyama T; Miyamoto M; Sakakibara R; Shimo Y; Hattori N; Kuwabara S; Yamamoto T; Kaji Y; Hirano S; Kadowaki T; Hirata K; Kanto NMPD investigators
[Ad] Endereço:Department of Neurology, Dokkyo Medical University, Tochigi, Japan.
[Ti] Título:Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study.
[So] Source:J Neurol Neurosurg Psychiatry;88(11):953-959, 2017 Nov.
[Is] ISSN:1468-330X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To investigate the impact of sleep disturbances on Parkinson's disease (PD) clinical motor subtypes and disease-related disability in a multicentre setting. METHODS: We report a cross-sectional relationship between sleep-related symptoms and clinical motor subtypes (tremor dominant (TD); intermediate; postural instability and gait disturbances (PIGDs)) identified in a multicentre study, including 436 patients with PD and 401 age-matched controls. PD-related sleep problems (PD-SP), excessive daytime sleepiness (EDS) and probable REM sleep behaviour disorder (pRBD) were evaluated using the PD sleep scale (PDSS)-2, Epworth Sleepiness Scale (ESS) and RBD screening questionnaire-Japanese version (RBDSQ-J), respectively. RESULTS: PD-SP (PDSS-2 ≥18; 35.1% vs 7.0%), EDS (ESS ≥10; 37.8% vs 15.5%) and pRBD (RBDSQ-J ≥5; 35.1% vs 7.7%) were more common in patients with PD than in controls. The prevalence of restless legs syndrome did not differ between patients with PD and controls (3.4% vs 2.7%). After adjusting for age, sex, disease duration and Movement Disorder Society-Unified PD Rating Scale (MDS-UPDRS) part III score, the PIGD group had higher PDSS-2 and ESS scores than the TD group. The RBDSQ-J scores did not differ among the TD, intermediate and PIGD groups. A stepwise regression model predicting the MDS-UPDRS part II score identified the Hoehn and Yahr stage, followed by the number of sleep-related symptoms (PD-SP, EDS and pRBD), disease duration, MDS-UPDRS part III score, PIGD subtype, depression and MDS-UPDRS part IV score as significant predictors. CONCLUSION: Our study found a significant relationship between sleep disturbances and clinical motor subtypes. An increased number of sleep-related symptoms had an impact on disease-related disability.
[Mh] Termos MeSH primário: Avaliação da Deficiência
Distúrbios do Sono por Sonolência Excessiva/classificação
Distúrbios do Sono por Sonolência Excessiva/diagnóstico
Doença de Parkinson/classificação
Doença de Parkinson/diagnóstico
Transtorno do Comportamento do Sono REM/classificação
Transtorno do Comportamento do Sono REM/diagnóstico
[Mh] Termos MeSH secundário: Idoso
Estudos de Casos e Controles
Estudos Transversais
Distúrbios do Sono por Sonolência Excessiva/epidemiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Exame Neurológico
Doença de Parkinson/epidemiologia
Transtorno do Comportamento do Sono REM/epidemiologia
Estatística como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE
[do] DOI:10.1136/jnnp-2017-316136


  6 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28833467
[Au] Autor:Iranzo A; Santamaría J; Valldeoriola F; Serradell M; Salamero M; Gaig C; Niñerola-Baizán A; Sánchez-Valle R; Lladó A; De Marzi R; Stefani A; Seppi K; Pavia J; Högl B; Poewe W; Tolosa E; Lomeña F
[Ad] Endereço:Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.
[Ti] Título:Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder.
[So] Source:Ann Neurol;82(3):419-428, 2017 Sep.
[Is] ISSN:1531-8249
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine the usefulness of dopamine transporter (DAT) imaging to identify idiopathic rapid eye movement sleep behavior disorder (IRBD) patients at risk for short-term development of clinically defined synucleinopathy. METHODS: Eighty-seven patients with polysomnography-confirmed IRBD underwent I-FP-CIT DAT-SPECT. Results were compared to 20 matched controls without RBD who underwent DAT-SPECT. In patients, FP-CIT uptake was considered abnormal when values were two standard deviations below controls' mean uptake. After DAT-SPECT, patients were followed up during 5.7 ± 2.2 (range, 2.6-9.9) years. RESULTS: Baseline DAT deficit was found in 51 (58.6%) patients. During follow-up, 25 (28.7%) subjects developed clinically defined synucleinopathy (Parkinson's disease in 11, dementia with Lewy bodies in 13, and multiple system atrophy in 1) with mean latency of 3.2 ± 1.9 years from imaging. Kaplan-Meier survival analysis showed increased risk of incident synucleinopathy in patients with abnormal DAT-SPECT than with normal DAT-SPECT (20% vs 6% at 3 years, 33% vs 18% at 5 years; log rank test, p = 0.006). Receiver operating characteristics curve revealed that reduction of FP-CIT uptake in putamen greater than 25% discriminated patients with DAT deficit who developed synucleinopathy from patients with DAT deficit that remained disease free after 3 years of follow-up. At 5-year follow-up, DAT-SPECT had 75% sensitivity, 51% specificity, 44% positive predictive value, 80% negative predictive value, and likelihood ratio 1.54 to predict synucleinopathy. INTERPRETATION: DAT-SPECT identifies IRBD patients at short-term risk for synucleinopathy. Decreased FP-CIT putamen uptake greater than 25% predicts synucleinopathy after 3 years' follow-up. These observations may be useful to select candidates for disease modification trials in IRBD. Ann Neurol 2017;82:419-428.
[Mh] Termos MeSH primário: Encéfalo/diagnóstico por imagem
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Doença por Corpos de Lewy/diagnóstico por imagem
Doença de Parkinson/diagnóstico por imagem
Transtorno do Comportamento do Sono REM/diagnóstico por imagem
Sinucleínas/metabolismo
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Biomarcadores
Encéfalo/metabolismo
Progressão da Doença
Feminino
Seres Humanos
Doença por Corpos de Lewy/metabolismo
Masculino
Meia-Idade
Doença de Parkinson/metabolismo
Polissonografia
Transtorno do Comportamento do Sono REM/metabolismo
Tomografia Computadorizada de Emissão de Fóton Único
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Dopamine Plasma Membrane Transport Proteins); 0 (Synucleins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1002/ana.25026


  7 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28684245
[Au] Autor:Stokholm MG; Iranzo A; Østergaard K; Serradell M; Otto M; Svendsen KB; Garrido A; Vilas D; Borghammer P; Santamaria J; Møller A; Gaig C; Brooks DJ; Tolosa E; Pavese N
[Ad] Endereço:Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.
[Ti] Título:Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.
[So] Source:Lancet Neurol;16(10):789-796, 2017 Oct.
[Is] ISSN:1474-4465
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Findings from longitudinal follow-up studies in patients with idiopathic rapid-eye-movement sleep behaviour disorder (IRBD) have shown that most patients will eventually develop the synucleinopathies Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Neuroinflammation in the form of microglial activation is present in synucleinopathies and is a potential therapeutic target to halt or delay the neurodegenerative process. We aimed to investigate whether neuroinflammation is present in patients with IRBD and its possible relation to nigrostriatal dopamine function. METHODS: In this prospective, case-control, PET study, patients with IRBD and no clinical evidence of parkinsonism and cognitive impairment were recruited from tertiary sleep centres in Spain (Barcelona) and Denmark (Aarhus). We included patients with polysomnography-confirmed IRBD according to established criteria. Healthy controls were recruited through newspaper advertisements. Controls had no motor or cognitive complaints, a normal neurological examination, and a mean group age similar to the IRBD group. In patients with IRBD, we assessed microglial activation in the substantia nigra, putamen, and caudate with C-PK11195 PET, and dopaminergic axon terminal function in the putamen and caudate with F-DOPA PET. Controls underwent either C-PK11195 PET or F-DOPA PET. We compared F-DOPA uptake and C-PK11195 binding potential between groups with an unpaired, two-tailed Student's t test. FINDINGS: Between March 23, 2015, and Oct 19, 2016, we recruited 20 consecutive patients with IRBD and 19 healthy controls. C-PK11195 binding was increased on the left side of the substantia nigra in patients with IRBD compared with controls (Student's t test, mean difference 0·153 [95% CI 0·055 to 0·250], p=0·003), but not on the right side (0·121 [-0·007 to 0·250], p=0·064). C-PK11195 binding was not significantly increased in the putamen and caudate of patients with IRBD. F-DOPA uptake was reduced in IRBD in the left putamen (-0·0032 [-0·0044 to -0·0021], p<0·0001) and right putamen (-0·0032 [-0·0044 to -0·0020], p<0·0001), but not in the caudate. INTERPRETATION: In patients with IRBD, increased microglial activation was detected by PET in the substantia nigra along with reduced dopaminergic function in the putamen. Further studies, including more participants than were in this study and longitudinal follow-up, are needed to support our findings and evaluate whether the presence of activated microglia in patients with IRBD represents a marker of short-term conversion to a clinically defined synucleinopathy in the near future. FUNDING: Danish Council for Independent Research, Instituto de Salud Carlos III (Spain).
[Mh] Termos MeSH primário: Núcleo Caudado/metabolismo
Neurônios Dopaminérgicos/metabolismo
Microglia/metabolismo
Tomografia por Emissão de Pósitrons/métodos
Putamen/metabolismo
Transtorno do Comportamento do Sono REM
Substância Negra/metabolismo
[Mh] Termos MeSH secundário: Idoso
Amidas
Axônios/metabolismo
Estudos de Casos e Controles
Núcleo Caudado/diagnóstico por imagem
Dinamarca
Di-Hidroxifenilalanina/análogos & derivados
Feminino
Seres Humanos
Inflamação/metabolismo
Isoquinolinas
Masculino
Meia-Idade
Estudos Prospectivos
Putamen/diagnóstico por imagem
Transtorno do Comportamento do Sono REM/diagnóstico por imagem
Transtorno do Comportamento do Sono REM/imunologia
Transtorno do Comportamento do Sono REM/metabolismo
Espanha
Substância Negra/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 ((R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide); 0 (Amides); 0 (Isoquinolines); 2C598205QX (fluorodopa F 18); 63-84-3 (Dihydroxyphenylalanine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE


  8 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28645156
[Au] Autor:Jozwiak N; Postuma RB; Montplaisir J; Latreille V; Panisset M; Chouinard S; Bourgouin PA; Gagnon JF
[Ad] Endereço:Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada.
[Ti] Título:REM Sleep Behavior Disorder and Cognitive Impairment in Parkinson's Disease.
[So] Source:Sleep;40(8), 2017 Aug 01.
[Is] ISSN:1550-9109
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Study Objectives: REM sleep behavior disorder (RBD) is a parasomnia affecting 33% to 46% of patients with Parkinson's disease (PD). The existence of a unique and specific impaired cognitive profile in PD patients with RBD is still controversial. We extensively assessed cognitive functions to identify whether RBD is associated with more severe cognitive deficits in nondemented patients with PD. Methods: One hundred sixty-two participants, including 53 PD patients with RBD, 40 PD patients without RBD, and 69 healthy subjects, underwent polysomnography, a neurological assessment and an extensive neuropsychological exam to assess attention, executive functions, episodic learning and memory, visuospatial abilities, and language. Results: PD patients with RBD had poorer and clinically impaired performance in several cognitive tests compared to PD patients without RBD and healthy subjects. These two latter groups were similar on all cognitive measures. Mild cognitive impairment (MCI) diagnosis frequency was almost threefold higher in PD patients with RBD compared to PD patients without RBD (66% vs. 23%, p < .001). Moreover, subjective cognitive decline was reported in 89% of PD patients with RBD compared to 58% of PD patients without RBD (p = .024). Conclusions: RBD in PD is associated with a more impaired cognitive profile and higher MCI diagnosis frequency, suggesting more severe and widespread neurodegeneration. This patient subgroup and their caregivers should receive targeted medical attention to better detect and monitor impairment and to enable the development of management interventions for cognitive decline and its consequences.
[Mh] Termos MeSH primário: Disfunção Cognitiva/complicações
Disfunção Cognitiva/psicologia
Doença de Parkinson/complicações
Doença de Parkinson/psicologia
Transtorno do Comportamento do Sono REM/complicações
Transtorno do Comportamento do Sono REM/psicologia
[Mh] Termos MeSH secundário: Idoso
Atenção
Disfunção Cognitiva/patologia
Disfunção Cognitiva/fisiopatologia
Função Executiva
Feminino
Seres Humanos
Linguagem
Masculino
Memória Episódica
Meia-Idade
Testes Neuropsicológicos
Doença de Parkinson/patologia
Doença de Parkinson/fisiopatologia
Polissonografia
Transtorno do Comportamento do Sono REM/patologia
Transtorno do Comportamento do Sono REM/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170625
[St] Status:MEDLINE
[do] DOI:10.1093/sleep/zsx101


  9 / 917 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28615430
[Au] Autor:Iranzo A; Stefani A; Serradell M; Martí MJ; Lomeña F; Mahlknecht P; Stockner H; Gaig C; Fernández-Arcos A; Poewe W; Tolosa E; Högl B; Santamaria J; SINBAR (Sleep Innsbruck Barcelona) group
[Ad] Endereço:From the Neurology Service (A.I., M.S., M.J.M., C.G., A.F.-A., E.T., J.S.) and Nuclear Medicine Service (F.L.), Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Spain; and Department of Neurology (A.S., P.M., H.S., W.P., B.H.), Medical University Innsbruck, Austria. airanzo@clinic.ub.es.
[Ti] Título:Characterization of patients with longstanding idiopathic REM sleep behavior disorder.
[So] Source:Neurology;89(3):242-248, 2017 Jul 18.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the presence of prodromal markers of Parkinson disease (PD) in patients with longstanding idiopathic REM sleep behavior disorder (IRBD), a small subgroup of individuals with IRBD with long-term follow-up thought not to be at risk of developing PD. METHODS: Demographic, clinical, and neuroimaging markers of PD were evaluated in 20 patients with polysomnographic-confirmed longstanding IRBD and in 32 matched controls. RESULTS: Patients were 16 men and 4 women with mean age of 72.9 ± 8.6 years and mean follow-up from IRBD diagnosis of 12.1 ± 2.6 years. Patients more often had objective smell loss (35% vs 3.4%, = 0.003), constipation (50% vs 15.6%, = 0.008), and mild parkinsonian signs (45% vs 18.8%, = 0.042) than controls. Unified Parkinson's Disease Rating Scale motor score was higher in patients than in controls (5.6 ± 3.5 vs 2.0 ± 2.1, < 0.0001). Dopamine transporter imaging showed decreased striatal uptake in 82.4% of the patients and transcranial sonography found substantia nigra hyperechogenicity in 35.3%. α-Synuclein aggregates were found in 3 of 6 patients who underwent colon or submandibular gland biopsies. All 20 patients showed clinical, neuroimaging, or histologic markers of PD. Probability of prodromal PD (according to recent Movement Disorders Society research criteria) was higher in patients than in controls (<0.0001), and 45% of patients surpassed 80% probability. CONCLUSIONS: Prodromal PD markers are common in individuals with longstanding IRBD, suggesting that they are affected by an underlying neurodegenerative process. This observation may be useful for the design of disease-modifying trials to prevent PD onset in IRBD.
[Mh] Termos MeSH primário: Doença de Parkinson/diagnóstico
Doença de Parkinson/fisiopatologia
Transtorno do Comportamento do Sono REM/diagnóstico
Transtorno do Comportamento do Sono REM/fisiopatologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Encéfalo/diagnóstico por imagem
Encéfalo/metabolismo
Mapeamento Encefálico
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Sintomas Prodrômicos
Fatores de Risco
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170616
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000004121


  10 / 917 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28552865
[Au] Autor:Orimo S
[Ad] Endereço:Department of Neurology, Kanto Central Hospital.
[Ti] Título:New development of diagnosis and treatment for Parkinson's disease.
[So] Source:Rinsho Shinkeigaku;57(6):259-273, 2017 06 28.
[Is] ISSN:1882-0654
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:New methods for the diagnosis and new treatments for Parkinson's disease (PD) were explained. As imaging tools, neuromelanin imaging using brain MRI, meta-iodobenzylguanidine (MIBG) cardiac scintigraphy, dopamine transporter scintigraphy, and transcranial sonography were introduced. Olfactory dysfunction and REM sleep behavior disorders (RBD), which are important non-motor symptoms, and the new Clinical Criteria for PD launched by Movement Disorder Society (MDS) were also described. Investigative new medications and new anti-PD medications, which recently became available in Japan, were introduced. I explained the rationale of early treatment, strategy of initial treatment, the significance of continuous dopaminergic stimulation, strategy of treatment for advanced PD, and deep brain stimulation as a surgical treatment together with promising new treatments including gene therapy and cell transplantation.
[Mh] Termos MeSH primário: Antiparkinsonianos
Terapia Baseada em Transplante de Células e Tecidos
Estimulação Encefálica Profunda
Terapia por Estimulação Elétrica
Terapia Genética
Doença de Parkinson/diagnóstico
Doença de Parkinson/terapia
[Mh] Termos MeSH secundário: 3-Iodobenzilguanidina
Proteínas da Membrana Plasmática de Transporte de Dopamina
Neurônios Dopaminérgicos
Seres Humanos
Imagem por Ressonância Magnética
Imagem de Perfusão do Miocárdio
Neuroimagem
Transtornos do Olfato
Doença de Parkinson/diagnóstico por imagem
Transtorno do Comportamento do Sono REM
Cintilografia
Substância Negra/diagnóstico por imagem
Ultrassonografia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Dopamine Plasma Membrane Transport Proteins); 35MRW7B4AD (3-Iodobenzylguanidine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170530
[St] Status:MEDLINE
[do] DOI:10.5692/clinicalneurol.cn-000969



página 1 de 92 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde